A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Public ClinicalTrials.gov record NCT03845166. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination with atezolizumab, and in combination with avelumab to subjects with advanced solid tumors.
Study identification
- NCT ID
- NCT03845166
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 325 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 20, 2019 (Actual)
- Primary completion
- Aug 31, 2026 (Estimated)
- Completion
- May 31, 2027 (Estimated)
- Last update posted
- Nov 19, 2024
2019 – 2027
United States locations
- U.S. sites
- 40
- U.S. states
- 21
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exelixis Clinical Site #6 | Duarte | California | 91010 | — |
| Exelixis Clinical Site #49 | La Jolla | California | 92093 | — |
| Exelixis Clinical Site #7 | Los Angeles | California | 90025 | — |
| Exelixis Clinical Site #84 | Los Angeles | California | 90095 | — |
| Exelixis Clinical Site #66 | San Francisco | California | 94158 | — |
| Exelixis Clinical Site #71 | Stanford | California | 94305 | — |
| Exelixis Clinical Site #15 | Lake Mary | Florida | 32746 | — |
| Exelixis Clinical Site #24 | Miami | Florida | 33136 | — |
| Exelixis Clinical Site #11 | Atlanta | Georgia | 30322 | — |
| Exelixis Clinical Site #80 | Atlanta | Georgia | 30342 | — |
| Exelixis Clinical Site #41 | Iowa City | Iowa | 52242 | — |
| Exelixis Clinical Site #36 | Westwood | Kansas | 66205 | — |
| Exelixis Clinical Site #62 | Scarborough | Maine | 04074 | — |
| Exelixis Clinical Site #44 | Baltimore | Maryland | 21201 | — |
| Exelixis Clinical Site #4 | Boston | Massachusetts | 02215 | — |
| Exelixis Clinical Site #45 | Ann Arbor | Michigan | 48109 | — |
| Exelixis Clinical Site #2 | Grand Rapids | Michigan | 49546 | — |
| Exelixis Clinical Site #25 | Saint Paul | Minnesota | 55101 | — |
| Exelixis Clinical Site #13 | Omaha | Nebraska | 68130 | — |
| Exelixis Clinical Site #9 | East Brunswick | New Jersey | 08816 | — |
| Exelixis Clinical Site #83 | New Brunswick | New Jersey | 08903 | — |
| Exelixis Clinical Site #86 | New York | New York | 10021 | — |
| Exelixis Clinical Site #35 | New York | New York | 10029 | — |
| Exelixis Clinical #78 | New York | New York | 10065 | — |
| Exelixis Clinical Site #85 | The Bronx | New York | 10461 | — |
| Exelixis Clinical #74 | Cincinnati | Ohio | 45219 | — |
| Exelixis Clinical Site #60 | Cleveland | Ohio | 44106 | — |
| Exelixis Clinical Site #59 | Hershey | Pennsylvania | 17033 | — |
| Exelixis Clinical Site #58 | Philadelphia | Pennsylvania | 19107 | — |
| Exelixis Clinical Site #12 | Pittsburgh | Pennsylvania | 15232 | — |
| Exelixis Clinical Site #61 | Charleston | South Carolina | 29425 | — |
| Exelixis Clinical Site #50 | Myrtle Beach | South Carolina | 29572 | — |
| Exelixis Clinical Site #33 | Germantown | Tennessee | 38138 | — |
| Exelixis Clinical Site #87 | Nashville | Tennessee | 37203 | — |
| Exelixis Clinical Site #3 | Houston | Texas | 77030 | — |
| Exelixis Clinical Site #1 | San Antonio | Texas | 78229 | — |
| Exelixis Clinical Site #5 | Salt Lake City | Utah | 84112 | — |
| Exelixis Clinical Site #8 | Charlottesville | Virginia | 22903 | — |
| Exelixis Clinical Site #43 | Richmond | Virginia | 23219 | — |
| Exelixis Clinical Site #26 | Spokane | Washington | 99208 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03845166, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2024 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03845166 live on ClinicalTrials.gov.